Key Insights on Gross Profit: Perrigo Company plc vs MiMedx Group, Inc.

Comparing Gross Profit Trends: Perrigo vs. MiMedx (2014-2023)

__timestamp	MiMedx Group, Inc.	Perrigo Company plc
Wednesday, January 1, 2014	105558000	1447700000
Thursday, January 1, 2015	167094000	1712400000
Friday, January 1, 2016	212608000	2051800000
Sunday, January 1, 2017	285920000	1979500000
Monday, January 1, 2018	322725000	1831500000
Tuesday, January 1, 2019	256174000	1773300000
Wednesday, January 1, 2020	208904000	1815200000
Friday, January 1, 2021	215332000	1416200000
Saturday, January 1, 2022	219525000	1455400000
Sunday, January 1, 2023	266843000	1680400000

Cracking the code

A Tale of Two Companies: Gross Profit Trends from 2014 to 2023

In the ever-evolving landscape of the pharmaceutical and biotech industries, understanding financial health is crucial. This analysis delves into the gross profit trends of Perrigo Company plc and MiMedx Group, Inc. over the past decade. Perrigo, a global leader in over-the-counter health products, consistently outperformed MiMedx, a regenerative medicine company, in terms of gross profit. From 2014 to 2023, Perrigo's gross profit averaged around 1.7 billion, peaking in 2016 with a 20% increase from 2014. Meanwhile, MiMedx saw a steady rise, with a notable 206% growth from 2014 to 2018, reflecting its expanding market presence. However, Perrigo's gross profit remained approximately eight times higher than MiMedx's throughout the period. These insights highlight the contrasting growth trajectories and market strategies of these two industry players.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025